Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» HIV
HIV
Merck to push for approval of HIV combo after Phase III success
Clinical Trials Arena
Thu, 03/13/25 - 11:31 am
Merck
HIV
clinical trials
Pifeltro
islatravir
FDA sets June date for Gilead's twice-yearly HIV PrEP
Pharmaphorum
Wed, 02/19/25 - 09:42 am
Gilead Sciences
FDA
PrEP
HIV
lenacapavir
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
Fierce Pharma
Wed, 02/12/25 - 11:16 am
Gilead Sciences
HIV
PrEP
lenacapavir
FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
MSN/Reuters
Tue, 01/14/25 - 06:08 pm
PBMs
FTC
cancer
HIV
drug pricing
OptumRx
CVS Caremark
Express Scripts
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wed, 12/11/24 - 11:40 am
Gilead Sciences
Biktarvy
patent cliffs
HIV
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Clinical Trials Arena
Sun, 12/1/24 - 11:46 am
Gilead Sciences
clinical trials
lenacapavir
HIV
PrEP
Gilead, Merck say HIV combo could be weekly, oral HIV drug
Pharmaphorum
Mon, 10/21/24 - 09:35 am
Gilead Sciences
Merck
HIV
antiretrovirals
clinical trials
islatravir
Sunleca
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
Fierce Pharma
Thu, 10/17/24 - 09:23 am
GSK
Gilead Sciences
PrEP
HIV
Apretude
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Reuters
Wed, 10/2/24 - 09:55 pm
Gilead Sciences
generics
HIV
lenacapavir
Gilead’s twice-yearly shot cut HIV infections by 96% in trial
CNBC
Thu, 09/12/24 - 10:28 am
Gilead Sciences
HIV
lenacapavir
US government appeals Gilead's trial win in Truvada, Descovy patent fight
Fierce Pharma
Tue, 07/9/24 - 12:01 pm
Gilead Sciences
HIV
PrEP
Truvada
Descovy
patents
Gilead's long-acting HIV drug superior to daily pill Truvada in study
Reuters
Thu, 06/20/24 - 11:20 am
Gilead Sciences
lenacapavir
HIV
Truvada
J&J to seek appeal of $150M verdict in long-spanning HIV meds off-label marketing case
Fierce Pharma
Mon, 06/17/24 - 10:31 pm
JNJ
Janssen
off-label
HIV
legal
whistleblower lawsuits
Prezista
Intelence
GSK raises profit outlook on strong vaccine, HIV drug sales
Reuters
Wed, 05/1/24 - 11:01 am
GSK
earnings
vaccines
HIV
WHO warns of growing resistance to GSK's HIV drug
Reuters
Wed, 03/6/24 - 11:46 am
GSK
HIV
Dolutegravir
drug resistance
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings
Reuters
Mon, 03/4/24 - 11:12 am
Obamacare
HIV
GSK’s Injectable HIV Drug Bests Pills in Patients with Medication Adherence Issues
BioSpace
Wed, 02/21/24 - 11:17 am
GSK
ViiV Healthcare
clinical trials
Cabenuva
HIV
Evotec Biologics expands partnership with ABL to develop antibodies against HIV
Biopharma Reporter
Mon, 02/12/24 - 11:10 pm
Evotec Biologics
ABL
CDMOs
HIV
antibodies
HIV: Three trials to watch in 2024
Clinical Trials Arena
Mon, 12/18/23 - 10:12 pm
HIV
clinical trials
ST Pharm
N-803
pirmitegravir
Gilead plans European trial of twice-yearly HIV PrEP drug
Pharmaphorum
Wed, 10/18/23 - 10:08 am
Gilead Sciences
clinical trials
HIV
PrEP
Sunlenca
Europe
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »